|Day Low/High||131.02 / 132.09|
|52 Wk Low/High||121.00 / 148.99|
Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.
A lot of investing is just waiting until the market hates good companies.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.
There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.
The Trump and Xi administrations are at least looking at the same page. That's more than nothing.
There is a good foundation for more positive action in the week ahead.
Before I give my recommendation I want to visit with the charts and indicators.
Both BA and JNJ appear to have made decisions in which the bottom line took precedent over what they stand for as a company.
I have the answer behind the conundrum that forces stocks up that should be going lower.
These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.
There are plenty of senior growth companies that can still move higher.
As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...
On days like today you realize how much of this market has been mauled by the bear.
"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.
Citigroup and Lululemon are on the radar this morning.
Does the Fed just keep injecting liquidity into money markets every single night forever?
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
3M, Caterpillar and Johnson & Johnson all face headwinds with a strong dollar.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.